Compare PZZA & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PZZA | ABCL |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 910.0M |
| IPO Year | 1995 | 2020 |
| Metric | PZZA | ABCL |
|---|---|---|
| Price | $32.19 | $3.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $45.00 | $7.75 |
| AVG Volume (30 Days) | 1.3M | ★ 3.8M |
| Earning Date | 05-25-2026 | 05-26-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $2,068,421,000.00 | $75,128,000.00 |
| Revenue This Year | $1.13 | N/A |
| Revenue Next Year | $0.96 | $6.30 |
| P/E Ratio | $34.62 | ★ N/A |
| Revenue Growth | 14.07 | ★ 160.56 |
| 52 Week Low | $30.16 | $1.89 |
| 52 Week High | $55.74 | $6.52 |
| Indicator | PZZA | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 59.75 |
| Support Level | $30.18 | $3.37 |
| Resistance Level | $40.23 | $3.84 |
| Average True Range (ATR) | 1.59 | 0.22 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 37.75 | 99.44 |
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.